TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00574080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Cisplatin
Description: 20 mg/m2 by continuous infusion Days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Cisplatin
Description: 20 mg/m2 by continuous infusion Days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Adriamycin
Description: 20 mg/m2 by continuous infusion Days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Adriamycin
Description: 20 mg/m2 by continuous infusion Days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Cyclophosphamide
Description: 800 mg/m2 by continuous infusion Days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Cyclophosphamide
Description: 800 mg/m2 by continuous infusion Days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Etoposide
Description: 80 mg/m2 by continuous infusion Days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Etoposide
Description: 80 mg/m2 by continuous infusion Days -3 and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Melphalan
Description: 50 mg/m2 Days -2 and -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 Melphalan
Description: 50 mg/m2 Days -2 and -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 and 2 Pegfilgrastim
Description: 6 mg Day +6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 and 2 Pegfilgrastim
Description: 6 mg Day +6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell Transplant (ASCT)
Description: Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Peripheral Blood Stem Cell Transplant (ASCT)
Description: Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Carmustine
Description: 300 mg/m2 Day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Carmustine
Description: 300 mg/m2 Day -5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Etoposide
Description: 200 mg/m2 Days -5, -4, -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Etoposide
Description: 200 mg/m2 Days -5, -4, -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Cytarabine
Description: 400 mg/m2 Days -5, -4, -3, -2
Study: NCT00665106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVA63035 Corticosteroid
Description: Single injection in the study eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVA63035 Corticosteroid
Description: Single injection in the study eye
Study: NCT04663633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability training
Description: Functional Rhythmic Core Stability exercises performed by the experimental group. 30 minutes insert included in the Gymnasts regular training.
Study: NCT02511938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu Only
Description: Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menu Plus intervention
Description: Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
Study: NCT01934582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treprostinil diethanolamine
Description: Open label study drug.
Study: NCT03819972

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dose response of Capolac®
Description: Capolac® (milk minerals high in calcium) dose is manipulated

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dose response of Capolac®
Description: Capolac® (milk minerals high in calcium) dose is manipulated

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dose response of Capolac®
Description: Capolac® (milk minerals high in calcium) dose is manipulated

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dose response of Capolac®
Description: Capolac® (milk minerals high in calcium) dose is manipulated
Study: NCT01543178

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: open-label rifaximin
Description: 550 mg three times a day (open-label)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open-label rifaximin
Description: 550 mg three times a day (open-label)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open-label rifaximin
Description: 550 mg three times a day (open-label)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: double-blind placebo
Description: 3 times a day (double-blind)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: double-blind rifaximin
Description: 550 mg three times a day (double-blind)
Study: NCT04156711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Description: Cycles of forearm ischemia and reperfusion by the inflation of a blood-pressure cuff over the systemic blood pressure for brief periods
Study: NCT01985932

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study: NCT04632082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepsychoeducation with personalized videos
Description: 1 session with a psychologist plus 1 video a week for 4 weeks chosen based on symptom presentation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychoeducation without personalized videos
Description: 1 session with a psychologist focused on reassurance and aspects of the outbreak
Study: NCT03660111

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: spirometry
Description: only measurement of spirometry
Study: NCT00574080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Cytarabine
Description: 400 mg/m2 Days -5, -4, -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Melphalan
Description: 140 mg/m2 Day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Melphalan
Description: 140 mg/m2 Day -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Dexamethasone
Description: 20 mg Days -5, -4, -3, -2, +4, +5, +6, +7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 2 Dexamethasone
Description: 20 mg Days -5, -4, -3, -2, +4, +5, +6, +7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 and 2 Bortezomib
Description: 1 mg/m2 Days -4, -1, +3, +7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant 1 and 2 Thalidomide
Description: 200 mg Days -4 to +5
Study: NCT00794612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd Femina Pocket BR (Lactic Acid)
Description: Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
Study: NCT03298139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 levels of gravity (1G, 1.8G, 0G).
Description: healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
Study: NCT04338100

Intervention type: PROCEDURE
Intervention: Follow-up at 14 days
Description: Point of care chest ultrasonography and 14-day follow-up to assess the evolution of the infection and care requirement (invasive ventilation or death)
Study: NCT03434951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride, Spinal
Description: Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride, Spinal
Description: Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride, Spinal
Description: Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo - Concentrate
Description: Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
Study: NCT06311695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Mammography
Description: Contrast Enhanced Mammography
Study: NCT00541515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous glucose sensors and insulin pump
Description: continuous glucose sensors and insulin pump
Study: NCT04099810

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: three-dimensional echocardiography
Description: A focused echocardiographic exam will be performed. In details will be acquired:~* high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~* Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition.
Study: NCT00714688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolonged release (PR) OROS methylphenidate 54 mg
Description: 18+36mg once daily for 13 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prolonged release (PR) OROS methylphenidate 72 mg
Description: 2x36mg once daily for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2xplacebo once daily for 13 weeks
Study: NCT00871455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
Study: NCT03735147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Description: Single dose of LAIV
Study: NCT03813602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Sativa
Description: 750 mg cannabis cigarette with 12.5% THC
Study: NCT02391571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naltrexone Capsules
Description: Oxycodone/Naltrexone to be taken with stable dose of Methadone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone to be taken with stable dose of Methadone

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 2 day placebo run in prior to test and active drug phase of study
Study: NCT00356213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-Y-gastric bypass
Description: laparoscopic gastric bypass
Study: NCT01243658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin
Study: NCT01760304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide / Formoterol
Description: Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated.
Study: NCT02875626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infracyanine
Description: In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
Study: NCT01243658

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01415921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine Bromide
Description: 15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
Study: NCT03074526

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Fluid
Description: Amniotic Fluid
Study: NCT03966157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Bridle
Description: Feeding tube secured with nasal bridle
Study: NCT01745432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADBLOCK
Description: Laparoscopic surgery
Study: NCT01936064

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jobelyn + Cyclophosphamide-Epirubicin6
Description: Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Cyclophosphamide - Epirubicin 6
Description: Routine drugs for the treatment of breast cancer to be used with Placebo
Study: NCT02088268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wound healing
Description: wound healing
Study: NCT01362738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFCA of PV and extra-PV triggers
Description: PVAI and isolation of extra PV triggers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAA isolation along with the conventional ablation strategy
Description: PVAI + isolation of extra PV triggers + LAA isolation
Study: NCT02355808

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Leaflet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Leaflet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Leaflet

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Leaflet
Study: NCT02580981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Lymphobastic Leukemia (ALL) Treatment Options
Description: Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
Study: NCT02095938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amisulpride
Description: Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
Study: NCT03206489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive high-frequency ventilation (nHFOV)
Description: noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure (nCPAP)
Description: nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
Study: NCT01971424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mg oxide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthy diet
Study: NCT04342910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: 200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.
Study: NCT02355808

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GP visit

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GP visit
Study: NCT04342910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: 250 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m\^2 administered as IV infusion on Days 1, and 15 of each 28-day cycle.
Study: NCT04539938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan
Description: 5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle
Study: NCT02523443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA
Description: Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCEA
Description: Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
Study: NCT02084589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor
Study: NCT04372186

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.
Study: NCT02785900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 33A
Description: 33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Volume equivalent to 10 mcg/kg, every 4 weeks via IV push

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: 75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
Study: NCT02785900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine
Description: 75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: 20 mg/m2 given IV x 5 days, every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Description: 20 mg/m2 given IV x 5 days, every 4 weeks
Study: NCT03074526

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Fluid
Description: Amniotic Fluid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Saline Placebo
Study: NCT01695967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: turbinate cauterization
Study: NCT01490996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral complex C3 curcumin + chemotherapy
Description: Daily oral capsule(s)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy only
Description: Standard care chemotherapy
Study: NCT01597050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R932333
Description: R393233 6% (60 mg/g), bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, bid
Study: NCT04832503

Intervention type: BEHAVIORAL
Intervention: PROMPT- treatment
Description: PROMPTs for Restructuring Oral Muscolar Phonetic Targets

Intervention type: BEHAVIORAL
Intervention: LNSOM-treatment
Description: Language Non-Speech Oral Motor Treatment
Study: NCT02308384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: CME, Start-package and status mail
Study: NCT02766530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PETMR study
Description: Use of PETMR study to evaluate the treatment response of breast cancer women
Study: NCT02024906

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein isolate (SPI)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: milk protein isolate (MPI)
Study: NCT04883632

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Saypha Volume Lidocaine
Description: correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Saypha Volume Lidocaine
Description: correction of Nasolabial Folds using injection of Saypha Volume Lidocaine manufactured in 2 different plants at Croma Pharma
Study: NCT01754467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT!
Description: Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
Study: NCT03386968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video gaming
Description: Children will visit Blythedale for 8 sessions, one 45-session visit per week, in place of one of the child's typical physical therapy sessions. During each session, children will play a video game on the X-Box Kinect system, using the games Kinect Adventures and Kinect Sports. The child will first play a Kinect Adventures game, which requires ambulating, ducking, and dodging one's way through an obstacle course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care physical therapy
Description: Children will attend their usual care physical therapy appointments at Blythedale.
Study: NCT00209417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodixanol 320-Arm 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol 300-Arm 2
Study: NCT00473798

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire